Molecular Partners AG (MOLN)
5.71
+0.29
(+5.35%)
USD |
NASDAQ |
Nov 22, 09:55
Molecular Partners Total Liabilities (Quarterly): 18.34M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 18.34M |
June 30, 2024 | 16.74M |
March 31, 2024 | 18.91M |
December 31, 2023 | 26.10M |
September 30, 2023 | 23.95M |
June 30, 2023 | 27.26M |
March 31, 2023 | 24.49M |
December 31, 2022 | 29.22M |
September 30, 2022 | 30.49M |
June 30, 2022 | 35.02M |
March 31, 2022 | 51.28M |
December 31, 2021 | 71.52M |
September 30, 2021 | 55.58M |
June 30, 2021 | 78.56M |
December 31, 2020 | 91.94M |
June 30, 2020 | 44.50M |
Date | Value |
---|---|
December 31, 2019 | 52.43M |
June 30, 2019 | 58.16M |
June 30, 2019 | 58.16M |
December 31, 2018 | 64.45M |
June 30, 2018 | 11.12M |
June 30, 2018 | 11.12M |
December 31, 2017 | 28.43M |
June 30, 2017 | 44.75M |
June 30, 2017 | 44.75M |
December 31, 2016 | 47.47M |
June 30, 2016 | 60.41M |
June 30, 2016 | 60.41M |
December 31, 2015 | 68.39M |
June 30, 2015 | 54.56M |
June 30, 2015 | 54.56M |
December 31, 2014 | 46.05M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
16.74M
Minimum
Jun 2024
91.94M
Maximum
Dec 2020
40.96M
Average
30.49M
Median
Sep 2022
Total Liabilities (Quarterly) Benchmarks
AC Immune SA | 135.61M |
CRISPR Therapeutics AG | 316.47M |
Addex Therapeutics Ltd | 1.164M |
NLS Pharmaceutics Ltd | 10.46M |
MoonLake Immunotherapeutics | 22.71M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 183.31M |
Shareholders Equity (Quarterly) | 164.96M |
Current Ratio | 14.33 |